Background--Varenicline is an efficacious smoking-cessation drug. However, previous meta-analyses provide conflicting results regarding its cardiovascular safety. The publication of several new randomized controlled trials (RCTs) provides an opportunity to reassess this potential adverse drug reaction.
V
arenicline is a partial nicotine receptor agonist that has been shown to be an efficacious smoking-cessation pharmacotherapy.
1,2 However, concerns exist regarding the cardiovascular safety of varenicline. Previous meta-analyses provided conflicting results regarding the association between varenicline and adverse cardiovascular events. [3] [4] [5] [6] In addition, the US Food and Drug Administration (FDA) has issued a warning regarding serious cardiovascular events that may occur in patients taking the drug. 7 Conclusive findings have been difficult to obtain given the rarity of these events and the limited size and duration of trials examining its use. However, safety data from more than a dozen new randomized controlled trials (RCTs) examining the use of varenicline for smoking cessation have nearly doubled the number of events of interest available, providing an opportunity to reassess this safety concern. We therefore performed a systematic review and meta-analysis of RCTs to examine the cardiovascular safety of varenicline.
Methods Search Strategy
This systematic review and meta-analysis was performed using a prespecified protocol, and the results are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 8 A detailed description of the search strategy can be found in Tables S1 through S3 . Briefly, we systematically searched MEDLINE (via Ovid), EMBASE (via Ovid), and the Cochrane Library in June 2015 by using Medical Subject Headings (MeSH) and EMTREE terms as well as keywords for varenicline. These search terms were then combined with a modified version of the Cochrane Collaboration's RCT hedge to restrict our search to RCTs. 9 The search was not restricted by date or language of publication. In addition, the references of included studies, as well as previous meta-analyses, were hand-searched for other potentially relevant studies. Unpublished data from a trial conducted by the authors (NCT00794573) were also screened for inclusion; this trial was published during the conduct of this meta-analysis. 10 
Study Selection
One reviewer (L.H.S.) screened the titles and abstracts of publications identified by the search. The full texts of potentially eligible articles were then screened, and those meeting our prespecified inclusion/exclusion criteria were included. Two reviewers (L.H.S. and L.T.) independently performed the full-text review, with disagreements resolved by consensus or a third reviewer (S.B.W.). Articles eligible for inclusion were those that (1) contained original data from RCTs examining the use of varenicline versus an inactive control (ie, placebo or a behavioral intervention applied equally in the varenicline and comparison groups; hereinafter referred to as placebo) in tobacco users and (2) reported the incidence of cardiovascular serious adverse events (SAEs) and/or all-cause mortality during the study treatment period (ie, the duration of use of varenicline or placebo) or up to 30 days after drug discontinuation. Studies combining the use of the study drug with any form of behavioral counseling were also included. Observational studies, studies of abstinence maintenance, case reports and case series, reviews, meta-analyses, commentaries, letters to the editor, conference proceedings, and abstracts were excluded. Articles published in a language other than English or French were also excluded.
Data Abstraction
Two reviewers (L.H.S. and L.T.) independently abstracted data, with discrepancies resolved by consensus or a third reviewer (S.B.W.). Abstracted information included trial name, first author, year published, countries in which participants were enrolled, sample size, length of treatment, varenicline dose, cardiovascular inclusion or exclusion criteria (eg, clinically significant cardiovascular disease [CVD], neurologic disorders, or cerebrovascular disease during the previous 6 months), participant demographic information (ie, age, sex, mean number of years smoked, and mean number of cigarettes smoked per day at baseline), and data pertaining to safety outcomes.
Outcomes
The primary outcome was incidence of cardiovascular SAEs (eg, myocardial infarction, unstable angina, coronary artery disease, need for coronary revascularization, arrhythmia, congestive heart failure, transient ischemic attack, stroke, sudden death, cardiovascular-related death). The secondary outcome was all-cause mortality. Only events that occurred during study treatment or within 30 days of drug discontinuation were included. Whenever possible, published outcome data were compared with results posted on ClinicalTrials.gov. When event rates differed for a given trial, we chose the source providing the most detailed classification of events (eg, in terms of determining whether reported SAEs were cardiovascular in nature and/or clarifying the timing of reported events in relation to study drug use).
Quality Assessment
Quality assessment of each included trial was performed by using the Cochrane Risk of Bias Tool. 11 This tool is used to assess threats to internal validity by assigning scores of "high," "low," or "unclear" risk of bias in the domains of sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting, and other potential sources of bias. Two reviewers (L.H.S. and L.T.) independently performed quality assessment, and discrepancies were resolved by consensus or a third reviewer (S.B.W.). All studies were included in the review and meta-analysis regardless of their quality.
Statistical Analysis
We used DerSimonian-Laird random-effects models to calculate relative risks (RRs) and corresponding 95% CIs. All analyses were conducted overall and then stratified by whether the trial was conducted in participants with a history of CVD. In our primary analysis, we used a 0.5 continuity correction to include data from RCTs that had study arms with zero events. This continuity correction allows for inclusion of zero event trials while maintaining analytic consistency. 12 Risk differences (RDs) with 95% CIs were also calculated; these analyses were stratified by treatment duration and CVD history. Heterogeneity was assessed by using an I 2 statistic.
Several sensitivity analyses were conducted to assess the robustness of our results. First, we repeated our analyses by using Mantel-Haenszel fixed-effects models. Inverse-variance weighting and the Peto approach were used to assess the impact of the choice of fixed-effects approach, given the small number of events in the individual trials. Second, we conducted influence analyses in which our random-effects analyses were repeated omitting 1 trial at a time to assess the impact of each individual RCT on the final pooled results. Third, we repeated our analyses excluding trials with zero events in one arm and then excluding trials with zero events in both arms to assess the impact of zero event trials on our results. Fourth, we repeated our primary analyses, including only trials with at least 100 participants. Finally, to assess for potential publication bias, a funnel plot was visually assessed, and an Egger's test for small study effects was performed. All analyses were performed by using R version 3. 
Results
Our electronic database search yielded 1564 potentially eligible studies for inclusion in our review ( Figure 1 ). We additionally assessed unpublished data from a trial conducted by the authors (NCT00794573); this trial was published during the conduct of this meta-analysis. 10 After the removal of duplicates and screening of titles and abstracts, 68 trials underwent full-text review. In total, 38 RCTs met all eligibility criteria and were included in our meta-analysis.
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Study Characteristics
Sample sizes ranged from 10 to 1510 patients with a median of 268 patients (Table) . A total of 7213 patients were randomized to varenicline and 5493 patients to placebo. The most common dose of varenicline was 1 mg twice daily, with some studies in which lower doses were prescribed. Length of treatment with varenicline ranged from 1 to 52 weeks, with the majority of studies treating patients for 12 weeks. Four studies examined CVD patients specifically (1 studied patients with a recent acute coronary syndrome, 1 studied patients with stable coronary artery disease, and 2 studied inpatients in which >50% were admitted for CVD). Seventeen RCTs examined smokers drawn from the general population, 5 studied smokers with mental illness (ie, schizophrenia, depression, bipolar disorder), 3 studied opioid-or cocaine-dependent tobacco smokers, 4 studied smokeless tobacco users, and 5 RCTs examined patients with other inclusion criteria such as specific age ranges or patients scheduled for surgery. Losses to follow-up varied between studies and ranged between 0% to 60%, with most studies reporting losses of <25%.
Quality Assessment
Overall, studies had a low risk of bias (Table S4) when assessed by using the Cochrane Risk of Bias tool. 11 A number of studies had an unclear risk of bias in the sequence generation and allocation concealment categories. In the blinding domain, 1 study had a high risk of bias as a result of a behavioral intervention-only comparison group. Two additional studies had an unclear risk of bias because of insufficient information to determine whether there was adequate blinding. Several studies had an unclear or high risk of bias in the category of outcome data because of high rates of loss to follow-up.
Patient Characteristics
The mean age of participants across all study arms ranged from 13.5 to 69.1 years, and the proportion of male participants ranged from 26.7% to 97.5% (Table S5 ). Among studies conducted in adult tobacco users, the mean number of years of use ranged from 10.9 to 51.5 years (Table) . In trials conducted in cigarette-smoking adults, the mean number of cigarettes smoked per day ranged from 10.7 to 26.0 (Table) .
Cardiovascular SAEs
Overall, event rates were low, with 14 of the 38 included studies reporting no cardiovascular SAEs during treatment or within 30 days of treatment discontinuation. As anticipated, RCTs conducted in patients with acute coronary syndromes or established stable CVD had a higher cumulative incidence of cardiovascular SAEs than did trials conducted in other populations. A total of 57 cardiovascular SAEs occurred in the 7213 patients randomized to varenicline, and 43 occurred in the 5493 patients randomized to placebo (Figure 2 ). When pooling the data across the 38 studies by using a randomeffects model, no significant difference was found for cardiovascular SAEs when comparing varenicline with placebo (RR 1.03, 95% CI 0.72-1.49). Similar results were found among patients with a history of CVD (RR 1.04, 95% CI 0.57-1.89) and without a history of CVD (RR 1.03, 95% CI 0.64-1.64). The corresponding RDs were 0.00 (95% CI 0.01-0.02) and 0.00 (95% CI 0.00-0.00), respectively (Figures S1 and S2).
All-Cause Mortality
Very few deaths occurred, with 32 of the 38 of studies reporting zero events in both study arms. The cause of death was reported for only half of the deaths that occurred, and half of these were cardiovascular in nature (n=5) ( Table S6) . A total of 11 deaths occurred in the 7213 patients randomized to varenicline and 9 occurred in the 5493 patients randomized to placebo (Figure 3 ). When data were pooled across trials, no difference in all-cause mortality was observed when comparing varenicline with placebo (RR 0.88, 95% CI 0.50-1.52). There was no detectable difference between patients with a history of CVD (RR 1.24, 95% CI 0.40-3.83) and those without a history of CVD (RR 0.77, 95% CI 0.40-1.48); however, CIs were wide because of the rarity of these events. Corresponding RDs were also calculated, with no detectable difference found between varenicline and placebo for all-cause mortality in both CVD (RD 0.00, 95% CI À0.01 to 0.01) and non-CVD patients (RD 0.00, 95% CI 0.00-0.00) ( Figures S3 and S4 ). 
Sensitivity Analyses
Sensitivity analyses that used fixed-effects models produced results that were consistent with those of our primary analyses (data not shown). An influence analysis performed by using random-effects models showed that no study had an overly large impact on the meta-analysis results (data not shown).
Results also remained consistent when repeating our primary analyses while excluding trials with zero events in one arm and then excluding trials with zero events in both arms (data not shown). When including only studies with >100 participants, results were consistent with those of our primary analysis (data not shown). Importantly, these analyses excluded the trial by Faessel et al, which was conducted in adolescents. Finally, visual inspection of a funnel plot ( Figure S5 ) and Egger's test (P=0.80) showed no evidence of publication bias. 
Discussion
Our study was designed to assess the cardiovascular safety of varenicline compared with placebo. Overall, cardiovascular SAEs and deaths were rare across trials. We found no increased risk of cardiovascular SAEs in participants randomized to varenicline. These findings were similar when stratified by participants with or without a history of CVD. Likewise, allcause mortality appeared similar between study populations and arms; however, the CIs were wide as a result of the rarity of these events and the relatively short treatment durations of included trials. Our results suggest that varenicline is not associated with increased cardiovascular risks compared with placebo.
Concerns regarding the cardiovascular safety of varenicline first emerged after an RCT that examined the use of varenicline in patients with stable CVD. The authors found numerically greater cardiovascular SAEs in the varenicline arm compared with the placebo arm when including events that occurred >30 days post treatment discontinuation. 13 Shortly after, the first of several meta-analyses examining the cardiovascular safety of varenicline was published. In their meta-analysis, Singh et al reported an increased incidence of cardiovascular SAEs when comparing varenicline with placebo. 3 However, the Singh et al meta-analysis was criticized for its choice of statistical approach, exclusion of zero event trials, and inclusion of events that occurred >30 days after drug discontinuation. 4, 50, 51 This may have resulted in an overestimation of the cardiovascular risk of varenicline.
A subsequent meta-analysis performed by Prochaska and Hilton, which included only events that occurred during or within 30 days of treatment with the study drug, found no difference in cardiovascular SAE incidence between varenicline and placebo groups despite the use of a variety of meta-analytic techniques. 4 A US Food and Drug Administration-mandated meta-analysis published by Ware et al that examined Pfizer-sponsored studies had similar findings. 5 This patient-level meta-analysis found no significant difference in rates of cardiovascular SAEs and low absolute risk of cardiovascular SAEs with the use of varenicline. Finally, a network meta-analysis conducted by Mills et al also found no evidence of cardiovascular harm with varenicline. 6 Our metaanalysis incorporated safety data from 16 new trials (including 1 conducted in the highest-risk patient population studied to date), nearly doubling the number of events available to pool. Our findings likewise suggest that these events are rare and not likely to be increased by the use of varenicline. These findings are also consistent with the results of several large cohort studies, which found no increased risk of cardiovascular SAEs when comparing individuals using varenicline with those using bupropion for smoking cessation. 52, 53 Ultimately, there is little epidemiological evidence to suggest that varenicline increases the risk of cardiovascular SAEs. Likewise, the biological mechanism by which varenicline could mediate cardiovascular SAEs remains unclear. Varenicline is a partial agonist of the a4-b2 nicotinic acetylcholine receptor (nAchR) and a full agonist of the a3-b4 and a7 nAchRs. These receptors have been shown to potentially modulate cardiovascular function. 11, [54] [55] [56] Varenicline activates a4-b2 and a7 nAchRs at rates similar to those of nicotine and is a greater agonist than nicotine at the a3-b4 nAchR. 57 However, it is unknown whether partial activation of these receptors can lead to major changes in cardiovascular health, as the role of these receptors in modulating the cardiovascular system is not well studied. It should be noted, however, that only a small portion of the detrimental effects of smoking could be expected to be mediated through nAchRs. The hemodynamic effects of nicotine arise mostly through activation of b-adrenergic receptors and not nAchRs, 58 and the vast majority of cardiovascular damage from smoking occurs as a result of the inflammation, oxidative stress, and hypercoagulable state caused by reactive oxygen species, carbon monoxide, and various particulates in tobacco smoke itself, not nicotine. 59 Given this, it appears unlikely that varenicline would increase cardiovascular risk through its activation of nAchRs, and if possible, the occurrence of such events would be extremely rare. This potential risk must also be considered in the context of the exceptional role of quitting smoking in reducing cardiovascular risk. 59, 60 The cardiovascular benefits of varenicline as an efficacious smokingcessation pharmacotherapy 61 far outweigh a speculative and extremely small potential increase in cardiovascular risk. Our review had several potential limitations. First, the events of interest were rare; therefore, despite pooling all available data, some treatment effects are accompanied by wider 95% CIs. Second, the analysis of secondary data includes reliance on individual study definitions of events to be counted as cardiovascular SAEs, and few studies reported independent adjudication of these events. Third, the potential for publication bias cannot be excluded; however, we found no evidence of this bias through Egger's test or visual examination of a funnel plot. Finally, one included study was unblinded. However, this study accounts for only 1.32% of the weight in our primary analysis of cardiovascular SAEs. Consequently, its inclusion is unlikely to have had an important impact on our overall treatment estimates.
Conclusion
This study was designed to assess the cardiovascular safety of varenicline compared with placebo. When pooling data from 38 RCTs, we found no evidence of an increased risk of cardiovascular SAEs or all-cause mortality with varenicline.
Results were similar among studies that included participants with and without a history of CVD. The benefits of varenicline as an efficacious smoking-cessation therapy outweigh any potential increased risk of cardiovascular harm.
